While multiple pharmaceutical companies look for vaccines to fight against coronavirus, others are getting into the business of reducing symptoms of the disease that often cause hospitalization.
Pharmaceutical giant Eli Lilly announced significant progress this week with its antibody treatment, called LY-CoV555, which appears to reduce the number of COVID-19 patients admitted for care.
"We believe that the data that we generated could be a real turning point in the fight against the coronavirus," said Andrew Adams, vice president of new therapeutic modalities and COVID-19 research.
"This is the first time we have a real understanding of the virus in the outpatient setting," he told Cheddar. "This data represents, really, a first in terms of potential options for patients in the future should this data bear out in bigger studies."
The drugmaker has also conducted a successful round of trials using rheumatoid arthritis drug baricitinib and antiviral medication remdesivir to reduce the number of days a patient requires hospitalization
When comparing the two options, Adams said deciding which treatment better suits patients depends on how long an individual has been living with the virus. People that have been hospitalized as a result of COVID-19 are more likely to have more internal damage "because of the inflammatory reaction to the virus" and likely benefit more from the baricitinib and remdesivir cocktail.
"In the prophylactic setting, for example, in the nursing homes, you likely wouldn't see the same kind of benefit as you'd see in a hospitalized setting because the immune system isn't as involved yet in the symptoms of the disease," he explained.
When it comes to costs, Eli Lilly says it's keeping families in mind, especially as medical bills and other expenses pile up amid the pandemic. Adams said the company is also working with physicians and patients to get a better understanding of their needs.
"The key guiding principle from our leadership team here at Lilly is making sure that patients who need access to our medicines in the coronavirus space get their access — around the globe, not just here in the U.S.," Adams said.
Chipmaker Nvidia is poised to release a quarterly report that could provide a better sense of whether the stock market has been riding an overhyped artificial intelligence bubble or is being propelled by a technological boom that’s still gathering momentum.
Cracker Barrel said late Tuesday it’s returning to its old logo after critics — including President Donald Trump — protested the company’s plan to modernize.
Low-value imports are losing their duty-free status in the U.S. this week as part of President Donald Trump's agenda for making the nation less dependent on foreign goods. A widely used customs exemption for international shipments worth $800 or less is set to end starting on Friday. Trump already ended the “de minimis” rule for inexpensive items sent from China and Hong Kong, but having to pay import taxes on small parcels from everywhere else likely will be a big change for some small businesses and online shoppers. Purchases that previously entered the U.S. without needing to clear customs will be subject to the origin country’s tariff rate, which can range from 10% to 50%.
Southwest Airlines will soon require plus-size travelers to pay for an extra seat in advance if they can't fit within the armrests of one seat. This change is part of several updates the airline is making. The new rule starts on Jan. 27, the same day Southwest begins assigning seats. Currently, plus-size passengers can pay for an extra seat in advance and later get a refund, or request a free extra seat at the airport. Under the new policy, refunds are still possible but not guaranteed. Southwest said in a statement it is updating policies to prepare for assigned seating next year.
Cracker Barrel is sticking with its new logo. For now. But the chain is also apologizing to fans who were angered when the change was announced last week.
Elon Musk on Monday targeted Apple and OpenAI in an antitrust lawsuit alleging that the iPhone maker and the ChatGPT maker are teaming up to thwart competition in artificial intelligence.
Hear from Gabino & Stephen Roche on Saphyre’s institutional AI platform that centralizes pre‑ and post‑trade data, redefining settlement speed and accuracy.
